Rhoen Klinikum AG (ETR:RHK) has been assigned a consensus recommendation of “Sell” from the seven analysts that are currently covering the stock, MarketBeat reports. Four research analysts have rated the stock with a sell recommendation and three have issued a hold recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is €21.96 ($25.53).
A number of analysts recently commented on RHK shares. Independent Research set a €25.50 ($29.65) price objective on Rhoen Klinikum and gave the company a “neutral” rating in a research note on Monday. Credit Suisse Group set a €16.50 ($19.19) target price on Rhoen Klinikum and gave the company a “sell” rating in a report on Monday. Berenberg Bank set a €26.20 ($30.47) target price on Rhoen Klinikum and gave the company a “neutral” rating in a report on Tuesday, July 30th. Warburg Research set a €25.50 ($29.65) price objective on Rhoen Klinikum and gave the stock a “neutral” rating in a report on Friday, May 3rd. Finally, Kepler Capital Markets set a €19.00 ($22.09) price target on Rhoen Klinikum and gave the company a “sell” rating in a report on Thursday, April 11th.
Shares of ETR RHK traded down €0.60 ($0.70) during mid-day trading on Monday, hitting €23.95 ($27.85). 16,507 shares of the company were exchanged, compared to its average volume of 43,281. The business’s 50 day moving average is €25.59. The company has a market capitalization of $1.60 billion and a price-to-earnings ratio of 37.42. The company has a debt-to-equity ratio of 8.66, a quick ratio of 1.66 and a current ratio of 1.80. Rhoen Klinikum has a 1-year low of €21.06 ($24.49) and a 1-year high of €27.40 ($31.86).
RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services primarily in the areas of cardiovascular, neurology, oncology, pulmonology, orthopedic, accident surgery; rehabilitation and nursing services to the elderly; and thoracic, tumors, and psychosomatic, as well as spinal, column, and joints diseases.
Further Reading: Arbitrage
Receive News & Ratings for Rhoen Klinikum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhoen Klinikum and related companies with MarketBeat.com's FREE daily email newsletter.